DAX25.113 +0,1%Est506.057 ±0,0%MSCI World4.343 -0,1%Top 10 Crypto9,4600 +4,3%Nas27.022 +0,4%Bitcoin63.294 +0,4%Euro1,1671 +0,2%Öl92,01 -1,4%Gold4.565 +1,6%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Infineon 623100 Rheinmetall 703000 Siemens Energy ENER6Y NVIDIA 918422 Micron Technology 869020 Dell Technologies A2N6WP SAP 716460 Lufthansa 823212 Deutsche Bank 514000 NEL ASA A0B733 Microsoft 870747 RENK RENK73 Deutsche Telekom 555750 AMD (Advanced Micro Devices) 863186 Plug Power A1JA81
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
USA und Iran wohl vor Einigung: DAX geht stabil ins Wochenende -- Dell von KI-Boom beflügelt -- Siemens Energy, Super Micro, SpaceX, Eli Lilly, IBM, Eventim, DHL, Unusual Machines im Fokus
Top News
So finden Sie die richtigen Informationen für Ihre Aktienauswahl So finden Sie die richtigen Informationen für Ihre Aktienauswahl
CTS Eventim-Aktie springt kräftig an: Starker Start ins neue Geschäftsjahr CTS Eventim-Aktie springt kräftig an: Starker Start ins neue Geschäftsjahr
Suche...
Jetzt kostenlos
bei finanzen.net anmelden
Watchlists & Musterdepots Tools & integriertes Trading Newsletter, Trading-Desk uvm.
Schon einen Account? Anmelden
Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

REGENXBIO Aktie

Kaufen
Verkaufen
REGENXBIO Aktien-Sparplan
5,92 EUR +0,01 EUR +0,24 %
STU
6,97 USD +0,09 USD +1,31 %
BTT
finanzen.net zero
REGENXBIO jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.296,85 Mio. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA140E0

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS75901B1070

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolRGNX

REGENXBIO Aktien News

DatumMeistgelesen
PR NewswireREGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 Million
PR NewswireFDA Accepts Biologics License Application for Mucopolysaccharidosis II Treatment
PR NewswireREGENXBIO Announces FDA Acceptance and Priority Review of the BLA for RGX-121 for MPS II
PR NewswireREGENXBIO Reports First Quarter 2025 Financial Results and Recent Operational Highlights
PR NewswireREGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 28th Annual Meeting
PR NewswireREGENXBIO to Participate in Upcoming Investor Conferences
PR NewswireREGENXBIO to Host Conference Call on May 12 to Discuss First Quarter 2025 Financial Results and Recent Operational Highlights
PR NewswireREGENXBIO REPORTS POSITIVE BIOMARKER DATA FROM AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY
PR NewswireREGENXBIO Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Updates
PR NewswireREGENXBIO Announces Presentations at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
PR NewswireREGENXBIO Announces Closing of Strategic Partnership with Nippon Shinyaku for MPS Diseases
PR NewswireREGENXBIO to Host Conference Call on March 13 to Discuss Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Highlights
PR NewswireREGENXBIO to Participate in Upcoming Investor Conferences
PR NewswireREGENXBIO Announces Presentations of RGX-121 at the 21st Annual WORLDSymposium 2025
PR NewswireREGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111 for MPS Diseases
PR NewswireAbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program
PR NewswireApollo Global Management and Workday Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600
PR NewswireREGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA
PR NewswireREGENXBIO to Host Webcast Discussing Pivotal Program and First Functional Data from the AFFINITY DUCHENNE® Trial of RGX-202
PR NewswireREGENXBIO Reports Third Quarter 2024 Financial Results and Recent Operational Updates
PR NewswireREGENXBIO to Participate in Upcoming Investor Conferences
PR NewswireREGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2024 Financial Results and Recent Operational Highlights
PR NewswireREGENXBIO Presents Positive Data from the Phase II Study of Subretinal ABBV-RGX-314 in Patients with Bilateral Wet AMD at AAO 2024
PR NewswireREGENXBIO Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting
PR NewswireREGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines Conference
PR NewswireREGENXBIO Appoints Mitchell Chan as Chief Financial Officer
PR NewswireREGENXBIO Announces Positive Data from Pivotal Dose Level of RGX-121 Demonstrating Long-Term Systemic Effect
PR NewswireREGENXBIO to Participate in Upcoming Investor Conferences
PR NewswireREGENXBIO Announces Presentation at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium
PR NewswireREGENXBIO to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
PR NewswireREGENXBIO Reports Second Quarter 2024 Financial Results and Recent Operational Highlights
PR NewswireREGENXBIO ANNOUNCES NEW POSITIVE DATA FROM AFFINITY DUCHENNE® TRIAL OF RGX-202
PR NewswireREGENXBIO to Host Conference Call on August 1 to Discuss Second Quarter 2024 Financial Results and Recent Operational Highlights
PR NewswireREGENXBIO Announces Expansion of AFFINITY DUCHENNE® Trial to Include a New Cohort of Younger Patients
PR NewswireREGENXBIO Announces Successful Pre-BLA Meeting with FDA to Support Accelerated Approval Pathway for RGX-121 for the Treatment of MPS II
PR NewswireREGENXBIO Announces Leadership Transition
PR NewswireREGENXBIO to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
PR NewswireREGENXBIO to Participate in Upcoming Investor Conferences
PR NewswireREGENXBIO Reports First Quarter 2024 Financial Results and Recent Operational Highlights
PR NewswireREGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2024 Financial Results and Recent Operational Highlights

REGENXBIO News

REGENXBIO News: auf dieser Seite finden Sie alle REGENXBIO News und Nachrichten zur REGENXBIO Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch REGENXBIO News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um REGENXBIO News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.